Slide 1: Controlled release for better healthcare – Interim report January-June 2025
Controlled release ) for better healthcare Interim report January - June, 2025
Slide 2: Significant events during the second quarter of 2025
Nanexa AB (PUBL) Significant events during the second quarter of 2025 In April, Nanexa announced that initial observations in the phase I study show that the 30 mg dose of NEX-22 has been well tolerated by patients with type 2 diabetes who have not previously received GLP-1 treatment. In April,
Slide 3: CEO's comment
CEO’s comment The second quarter of 2025 has continued to validate our core belief at Nanexa that slow-release medicines can transform how we dose and therefore treat people living with a range of conditions. Reducing the frequency of injections will improve compliance, treatment outcomes, and quali
Slide 4: CEO's comment (continued)
media representatives in the belief that by more widely communicating the Nanexa story, we can further raise interest in our PharmaShell platform. I’m delighted to report that Chris Spivey, Director of Industry Relations and Strategic Partnerships MJH Life Sciences and a highly respected voice in th
Slide 5: Financial comments
Financial comments Result and cash flow Second quarter 2025 Sales for the quarter amounted to SEK 2,705 (5,657) thousand, of which SEK 99 (1,123) thousand relates to evaluation agreements entered regarding the PharmaShell® technology, SEK 2,152 (3,766) thousand relates to the exclusivity agreement e
Slide 6: Employees, related party transactions, the share
Directors and the management are working actively to secure revenue from agreements with potential partners to develop the company and ensure long-term financing. Employees The number of employees as of June 30, 2025, was 15 (19), of which 4 (8) women and 11 (11) men. The average number of employees
Slide 7: Upcoming reporting
Upcoming reporting Nanexa AB provides recurring financial information according to the following plan. November 6, 2025, Interim report July-September 2025 The company’s financial year is January 1 – December 31. This interim report has not been subject to a comprehensive audit by the company’s audi
Slide 8: Income statement
Income statement Amounts in TSEK 01/04/2025 – 01/04/2024 – 01/01/2025 – 01/01/2024 – 01/01/2024 – 30/06/2025 30/06/2024 30/06/2025 30/06/2024 31/12/2024 Operating revenue Turnover 2,705 5,657 5,582 13,411 24,361 Capitalised development costs 6,128 5,080 10,904 11,365 22,331 Other income 7,239 85 7,3
Slide 9: Balance Sheet
Balance Sheet Amounts in TSEK 30/06/2025 30/06/2024 31/12/2024 Assets Fixed assets Intangible fixed assets 68,034 51,376 59,397 Tangible fixed assets 11,224 13,015 12,583 Financial fixed assets 370 263 316 Total fixed assets 79,627 64,654 72,296 Current assets Stock 570 118 495 Current receivables 6
Slide 10: Cash flow analysis
Cash flow analysis Amounts in TSEK 01/04/2025 – 01/04/2024 – 01/01/2025 – 01/01/2024 – 01/01/2024 – 30/06/2025 30/06/2024 30/06/2025 30/06/2024 31/12/2024 Current activities Operating result -5,237 -6,124 -13,450 -9,487 -26,062 Adjustments for items not included in cash flow 3,106 2,545 6,121 4,971
Slide 11: Change in equity
Change in equity Amounts in TSEK Share Not Fund for Share Profit/Loss Profit/Loss Total capital registered developme premium brought for the equity share nt work reserve forward period capital Amount as of 01/01/2025 17,562 0 51,318 317,961 -291,011 -24,905 70,925 Previous year's result -24,905 24,9
Slide 12: About Nanexa
About Nanexa Nanexa develops PharmaShell® – a drug delivery-system with great potential Nanexa is bringing the control, precision and versatility of Atomic Layer Deposition (ALD) technology to drug formulation. The company’s proprietary PharmaShell® platform is a unique drug delivery system that ena
Slide 13: PharmaShell unique features and Nanexa's business model
- Extends patent protection via new dosage forms on existing products. Sustainability - Depot drugs provide greater control over pharmaceutical substances and reduce the risk of them being handled incorrectly. - Patients avoid handling the drug, which reduces the risk, for example, of it being flush
Slide 14: Contact Nanexa AB
Contact David Westberg CEO +46-709 42 83 03 david.westberg@nanexa.se Nanexa AB Virdings Allé 2, SE-754 50 Uppsala, Sverige Phone: +46 (0) 18 100 300 Org nr. 556833-0285 info@nanexa.se Interim report January – June 2025 NANEXA AB (PUBL) 14